Synonym
ERW1041E; ERW-1041E; ERW 1041E;
IUPAC/Chemical Name
Quinolin-2-ylmethyl (S)-2-((((S)-3-bromo-4,5-dihydroisoxazol-5-yl)methyl)carbamoyl)pyrrolidine-1-carboxylate
InChi Key
JUUQCONZELUVJY-AZKAAPSKSA-N
InChi Code
InChI=1S/C29H36/c1-21-11-14-24(19-21)15-12-22(2)28-9-6-10-29(28)23(3)13-16-25-17-18-26-7-4-5-8-27(26)20-25/h4-5,7-8,11,17-18,20,24,28-29H,2-3,6,9-10,12-16,19H2,1H3/t24-,28+,29?/m1/s1
SMILES Code
C=C(C1[C@H](C(CC[C@@H]2CC(C)=CC2)=C)CCC1)CCC3=CC4=CC=CC=C4C=C3
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
384.61
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Chrobok NL, Bol JGJM, Jongenelen CA, Brevé JJP, El Alaoui S, Wilhelmus MMM, Drukarch B, van Dam AM. Characterization of Transglutaminase 2 activity inhibitors in monocytes in vitro and their effect in a mouse model for multiple sclerosis. PLoS One. 2018 Apr 24;13(4):e0196433. doi: 10.1371/journal.pone.0196433. eCollection 2018. PubMed PMID: 29689097; PubMed Central PMCID: PMC5918173.
2: Shinde AV, Su Y, Palanski BA, Fujikura K, Garcia MJ, Frangogiannis NG. Pharmacologic inhibition of the enzymatic effects of tissue transglutaminase reduces cardiac fibrosis and attenuates cardiomyocyte hypertrophy following pressure overload. J Mol Cell Cardiol. 2018 Apr;117:36-48. doi: 10.1016/j.yjmcc.2018.02.016. Epub 2018 Mar 2. PubMed PMID: 29481819; PubMed Central PMCID: PMC5892840.
3: Penumatsa KC, Toksoz D, Warburton RR, Kharnaf M, Preston IR, Kapur NK, Khosla C, Hill NS, Fanburg BL. Transglutaminase 2 in pulmonary and cardiac tissue remodeling in experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2017 Nov 1;313(5):L752-L762. doi: 10.1152/ajplung.00170.2017. Epub 2017 Aug 3. PubMed PMID: 28775095; PubMed Central PMCID: PMC5792178.
4: Dafik L, Albertelli M, Stamnaes J, Sollid LM, Khosla C. Activation and inhibition of transglutaminase 2 in mice. PLoS One. 2012;7(2):e30642. doi: 10.1371/journal.pone.0030642. Epub 2012 Feb 2. PubMed PMID: 22319575; PubMed Central PMCID: PMC3271093.
